Bristol-Myers Squibb Co (BMY) Shares Sold by Carroll Financial Associates Inc.

Carroll Financial Associates Inc. reduced its position in shares of Bristol-Myers Squibb Co (NYSE:BMY) by 7.3% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 19,047 shares of the biopharmaceutical company’s stock after selling 1,496 shares during the period. Carroll Financial Associates Inc.’s holdings in Bristol-Myers Squibb were worth $1,167,000 at the end of the most recent reporting period.

Several other large investors also recently made changes to their positions in BMY. Renaissance Technologies LLC increased its holdings in shares of Bristol-Myers Squibb by 108.5% during the second quarter. Renaissance Technologies LLC now owns 13,488,200 shares of the biopharmaceutical company’s stock worth $751,563,000 after buying an additional 7,020,200 shares in the last quarter. Franklin Resources Inc. increased its holdings in shares of Bristol-Myers Squibb by 185.2% during the second quarter. Franklin Resources Inc. now owns 6,098,935 shares of the biopharmaceutical company’s stock worth $339,830,000 after buying an additional 3,960,191 shares in the last quarter. Jennison Associates LLC increased its holdings in shares of Bristol-Myers Squibb by 16.2% during the third quarter. Jennison Associates LLC now owns 26,854,242 shares of the biopharmaceutical company’s stock worth $1,711,689,000 after buying an additional 3,735,453 shares in the last quarter. Janus Henderson Group PLC increased its holdings in shares of Bristol-Myers Squibb by 2,990.5% during the second quarter. Janus Henderson Group PLC now owns 3,634,128 shares of the biopharmaceutical company’s stock worth $202,494,000 after buying an additional 3,516,536 shares in the last quarter. Finally, Arrowstreet Capital Limited Partnership increased its holdings in shares of Bristol-Myers Squibb by 42,071.5% during the second quarter. Arrowstreet Capital Limited Partnership now owns 3,331,549 shares of the biopharmaceutical company’s stock worth $185,634,000 after buying an additional 3,323,649 shares in the last quarter. Institutional investors own 69.82% of the company’s stock.

Shares of Bristol-Myers Squibb Co (BMY) opened at $68.96 on Monday. The firm has a market capitalization of $112,582.92, a price-to-earnings ratio of 22.91, a P/E/G ratio of 2.14 and a beta of 1.09. Bristol-Myers Squibb Co has a 1-year low of $51.56 and a 1-year high of $70.05. The company has a quick ratio of 1.43, a current ratio of 1.55 and a debt-to-equity ratio of 0.59.

Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings results on Monday, February 5th. The biopharmaceutical company reported $0.68 EPS for the quarter, beating the Zacks’ consensus estimate of $0.67 by $0.01. The business had revenue of $5.45 billion for the quarter, compared to analysts’ expectations of $5.35 billion. Bristol-Myers Squibb had a net margin of 4.85% and a return on equity of 35.43%. The business’s quarterly revenue was up 3.9% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.63 earnings per share. equities analysts anticipate that Bristol-Myers Squibb Co will post 3.21 EPS for the current fiscal year.

The company also recently declared a quarterly dividend, which was paid on Thursday, February 1st. Shareholders of record on Friday, January 5th were given a dividend of $0.40 per share. The ex-dividend date was Thursday, January 4th. This represents a $1.60 dividend on an annualized basis and a yield of 2.32%. This is a boost from Bristol-Myers Squibb’s previous quarterly dividend of $0.39. Bristol-Myers Squibb’s dividend payout ratio is 271.19%.

Several research analysts have recently issued reports on the stock. Citigroup set a $78.00 price target on shares of Bristol-Myers Squibb and gave the stock a “buy” rating in a report on Friday. Morgan Stanley upgraded shares of Bristol-Myers Squibb from an “equal weight” rating to an “overweight” rating and upped their price target for the stock from $51.56 to $78.00 in a report on Thursday. BMO Capital Markets set a $51.00 price target on shares of Bristol-Myers Squibb and gave the stock a “sell” rating in a report on Wednesday, February 14th. Vetr downgraded shares of Bristol-Myers Squibb from a “hold” rating to a “sell” rating and set a $60.72 price target for the company. in a report on Thursday, February 8th. Finally, Leerink Swann upped their price target on shares of Bristol-Myers Squibb from $71.00 to $76.00 and gave the stock a “positive” rating in a report on Tuesday, February 6th. Three investment analysts have rated the stock with a sell rating, eight have assigned a hold rating and nine have issued a buy rating to the company. The company has a consensus rating of “Hold” and an average target price of $66.73.

In other Bristol-Myers Squibb news, EVP Sandra Leung sold 156,582 shares of the company’s stock in a transaction on Monday, December 4th. The shares were sold at an average price of $63.37, for a total transaction of $9,922,601.34. Following the sale, the executive vice president now owns 584,373 shares of the company’s stock, valued at $37,031,717.01. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Thomas J. Jr. Lynch sold 5,300 shares of the company’s stock in a transaction on Tuesday, December 12th. The shares were sold at an average price of $63.24, for a total transaction of $335,172.00. Following the sale, the executive vice president now directly owns 9,251 shares in the company, valued at approximately $585,033.24. The disclosure for this sale can be found here. Corporate insiders own 0.23% of the company’s stock.

WARNING: “Bristol-Myers Squibb Co (BMY) Shares Sold by Carroll Financial Associates Inc.” was posted by StockNewsTimes and is owned by of StockNewsTimes. If you are reading this piece on another site, it was illegally stolen and republished in violation of international trademark & copyright legislation. The original version of this piece can be viewed at https://stocknewstimes.com/2018/02/19/bristol-myers-squibb-co-bmy-shares-sold-by-carroll-financial-associates-inc.html.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply